Poli Angels
R. Joaquim Floriano, 72 - Conjunto 193 - sala 7, São Paulo, SP, 04534-000, Brazil
Overview
Poli Angels is a non-profit Angel Investor Association, focused on early-stage startups and composed predominantly of USP Polytechnic School students and alumni.
- Total investments
- 8
- Lead investments
- 2
- Investments · 12mo
- 2
- Active investors
- 3
Investment portfolio
- Guia da Alma
Participated · Equity · Nov 2025
Guia da Alma offers a B2B mental-health benefits platform that helps employers support the psychological well-being of their workforces through prevention, guidance and care resources. The company says its product is already validated and commercially consolidated among small and medium-sized enterprises, and a distribution partnership with Wellhub allows it to reach thousands of users every month. In 2025 the startup operated at breakeven while expanding its team and internal structure, more than doubling both revenue (versus 2024) and its customer base. Management has set a goal of doubling revenue every year and serving roughly 1,000 B2B customers by the end of 2027. Recent organisational changes include co-founder Liana moving from CMO to Chief Sales Officer and the hiring of Chris Fedrizzi as Chief Product Officer to oversee customer journey and product innovation. The company plans to allocate new capital toward technology enhancements, marketing and sales in order to scale already-validated commercial channels and improve user experience.
- Minha Coleta
Led · Equity · Nov 2025
Minha Coleta is a greentech offering a digital platform that integrates data, automates processes and facilitates reverse-logistics credits to improve the efficiency and compliance of waste-management operations. The solution targets Brazil’s fragmented waste chain, where more than 3,000 active landfills and low transparency create a sizeable market opportunity. After a shareholder dispute halted new business for about nine months and caused the loss of a client accounting for roughly 40 % of its revenue, the founder regained control and relaunched growth. In 2025 the company is on pace to nearly double the previous year’s revenue. Leveraging its new capital, the startup aims to scale operations and achieve a ten-fold expansion by 2026. The firm’s impact-driven model positions it well within the expanding ESG and impact-investment landscape in Brazil.
- Plano
Participated · Seed · Feb 2024
Plano offers an AI-driven platform that diagnoses users' financial health and delivers personalized action plans, with optional regular human advisory sessions. The product is available B2C and as a white-label solution for companies, and the startup pursues B2B2C partnerships to drive growth. Plano targets lower- and middle-income users and reports having helped more than 40,000 people get out of debt, optimized over R$160 million, provided over 500,000 hours of consultancy, and supported more than 20,000 clients to start investing. The company projects R$3.5 million in revenue in 2024 and aims to grow its database to over 300,000 users. Plano plans to use new funding to increase traction and volumetry of users in the B2B2C channel and to improve its solution to boost engagement and impact. Management expects a new Banco Central resolution effective July 1, 2024, to increase demand from banks and other financial institutions for financial-education solutions.
- ContaÁgil
Participated · Equity · Jul 2022
ContaÁgil offers a product that combines traditional accounting services with tax-routine management, a digital account for legal entities and a financial-management platform that supports boleto generation and invoice issuance. The company targets small businesses and aims to simplify bureaucracy for entrepreneurs by integrating financial and banking solutions into its platform. Management says recent funding will be used to accelerate customer acquisition and to further improve platform usability and processes. The startup reports a user base growing at about 15% per month and has just surpassed 1,000 active customers. ContaÁgil was created in Canoas (RS) and has incrementally expanded its product and go-to-market efforts via prior investor support. ContaÁgil is a SaaS platform offering 100% online accounting and financial services for small businesses, connecting fintechs, banks, entrepreneurs, accountants and financial advisors. Founded in 2017 by Fábio Pereira, Rubens Oleinski and Diógenes Dorneles da Rosa, the company is active in more than 46 cities across 11 Brazilian states. It plans to expand to all Brazilian states, triple its user base and eventually transform into a fintech. The R$1.3 million investment will be used to strengthen developer and sales teams, add new platform functionalities and differentiated service plans, and connect new solutions and products. Planned product work includes improved interfaces for ME and customized interfaces for MEIs, professional interfaces for accountants and advisors, and an open-banking feature to manage and move digital accounts. Management has opened over 30 positions to support rapid growth and customer-base expansion.
- SleepUp
Participated · Equity · Nov 2021
Founded by sisters Renata Bonaldi (engineer) and Paula Redondo (computer scientist), SleepUp offers an iOS and Android app that delivers cognitive-behavioral therapy for insomnia (CBT‑I), relaxation and meditation modules, plus telemedicine video/chat consultations and clinician dashboards. The platform is the first digital therapy for insomnia to receive Anvisa approval in Brazil and includes free and paid modules (sleep diary, clinical test, daily reports). The company integrates behavioral and clinical approaches and supports clinician monitoring via web dashboards. With a recently secured R$2 million investment, SleepUp is positioning to scale beyond direct-to-consumer access into B2B partnerships with pharma, payers and corporate health. Product roadmap includes development of algorithms, IoT sleep-monitoring integrations and artificial‑intelligence features to advance personalized and precision medicine. The startup plans internationalization efforts targeting Latin America, Europe and the United States while pursuing additional clinical and regulatory validation abroad.